There are 2789 resources available
1229P - Co-mutation of DNA damage repair (DDR) genes influence the efficiency of EGFR-TKIs in NSCLC patients harboring EGFR activating mutations
Presenter: Linlin Zhang
Session: ePoster Display
1196P - Pre-existing and acquired mechanisms of resistance to lorlatinib in previously treated patients (pts) with ALK+ advanced non-small cell lung cancer (NSCLC)
Presenter: Ben Solomon
Session: ePoster Display
1197P - First-line lorlatinib versus crizotinib in ALK-positive non-small cell lung cancer: Asian subgroup analysis of CROWN
Presenter: Qing Zhou
Session: ePoster Display
1198P - Anti-ALK autoantibodies in patients with ALK positive non-small cell lung cancer (NSCLC)
Presenter: Claudia Parisi
Session: ePoster Display
1235P - Comparative study between two 17-gray fractions versus thirteen 39-gray fractions palliative thoracic radiotherapy in advanced non-small cell lung carcinoma
Presenter: Syeda Tasmia
Session: ePoster Display
1236P - Poziotinib in NSCLC harbouring EGFR or HER2 exon 20 insertion mutation
Presenter: Arsela Prelaj
Session: ePoster Display
1201P - Real-world comparative effectiveness of 1L alectinib (ALC) vs crizotinib (CRZ) in patients (pts) with ALK+ advanced NSCLC with or without baseline CNS metastases (mets)
Presenter: Matthew Krebs
Session: ePoster Display